A massive market opportunity for Impedimed

Impedimed is a medical devices company that produces electronic devices capable of measuring the level of fluid in the human body, explains Shane Fitzgerald, Principal at Monash Investors. Their primary product, L-Dex, allows for the early detection of an otherwise incurable condition called Lymphedema, which affects cancer patients after treatment. “What gets us really excited about Impedimed is that it’s not just about Lymphedema, this is a platform business. They can measure body-fluid changes wherever.” One area in which they’re currently developing a new product is the early detection of chronic heart disease, a market many times larger than Lymphedema. Watch the full video to hear why he thinks Impedimed offers a lower risk profile than typical for medical device developers.

2 topics

1 stock mentioned

In 2012, Monash Investors was established by two of Australia’s most experienced fund managers in Simon Shields and Shane Fitzgerald. In 2018 Sebastian Correia joined the team and is now a Co-Portfolio Manager. Both Simon and Shane have over 30...

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.


Sign In or Join Free to comment